| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD2 | Synonyms | LFA-2, SRBC, T11 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1p13.1 | dbXrefs | |
| Description | CD2 molecule | ||||
| GTO ID | GTC3053 |
| Trial ID | NCT05397496 |
| Disease | B-Cell Non-Hodgkin's Lymphoma | B-Cell Acute Lymphoblastic Leukemia |
| Altered gene | CD19|CD3|CD2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | PIT565 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies |
| Year | 2022 |
| Country | Spain |
| Company sponsor | Novartis Pharmaceuticals |
| Other ID(s) | CPIT565A12101|2022-000367-45 |
| Cohort 1 | |||||||
|
|||||||